Form 4: Disc Medicine Exec Trades Shares Under 10b5-1 Plan

Disc Medicine COO Jonathan Yu executed trades involving company stock and stock options under a pre-arranged 10b5-1 plan.

Summary

• Jonathan Yu, Chief Operating Officer of Disc Medicine, Inc., reported transactions on July 7, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on March 17, 2026.
• Yu acquired 100 shares of common stock at $13.50 per share.
• Yu also disposed of 100 shares of common stock at $82.50 per share.
• Following these transactions, Yu beneficially owns 54,424 shares of common stock directly.
• Additionally, Yu holds a stock option to purchase 100 shares of common stock at an exercise price of $13.50, with an expiration date of December 28, 2032.
• The shares underlying this option vest over 48 months, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive stock transactions under a pre-established plan, which is standard practice and does not inherently signal positive or negative company performance.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.
• The COO continues to hold a significant number of shares (54,424) directly.
• The stock option held by the COO has a substantial number of shares underlying it (100), suggesting potential future equity participation.

Negatives

• The disposal of 100 shares at a significantly higher price ($82.50) than the acquisition price ($13.50) could be interpreted as the executive taking profits, though this is within a planned trading strategy.
• The acquisition of shares at a lower price ($13.50) while disposing of shares at a much higher price ($82.50) might suggest a significant price fluctuation or a strategy to acquire shares at a specific, lower price point within the plan.

Risks

• The Rule 10b5-1 plan itself is subject to market conditions and the company's performance, which could impact the value of the securities traded.
• The vesting of stock options is contingent on continued service, meaning any departure from the company before vesting would result in forfeiture.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans is a common and accepted practice for corporate insiders to trade company stock in a manner that avoids the appearance of insider trading. This filing indicates adherence to such a plan by a key executive at Disc Medicine.

Stakeholder Impact

• Shareholders: The transactions are conducted under a pre-approved plan, minimizing direct impact on share price due to insider trading concerns. The executive's continued ownership and option holdings suggest alignment with long-term company value.
• Employees: The vesting schedule for stock options indicates a focus on retaining key personnel.
• Management: Demonstrates adherence to corporate governance and compliance protocols regarding stock trading.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for future transactions.
• Vesting of stock options over the next 48 months, subject to continued employment.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Disc Medicine, Jonathan Yu, Stock Options, Beneficial Ownership, Common Stock, Executive Compensation